Elevation Oncology, Inc.

NASDAQ:ELEV

0.63 (USD) • At close September 6, 2024
Bedrijfsnaam Elevation Oncology, Inc.
Symbool ELEV
Munteenheid USD
Prijs 0.625
Beurswaarde 36,941,750
Dividendpercentage 0%
52-weken bereik 0.363 - 5.83
Industrie Biotechnology
Sector Healthcare
CEO Mr. Joseph J. Ferra Jr.
Website https://elevationoncology.com

An error occurred while fetching data.

Over Elevation Oncology, Inc.

Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors

Vergelijkbare Aandelen

Evelo Biosciences, Inc. logo

Evelo Biosciences, Inc.

EVLO

0 USD

NRx Pharmaceuticals, Inc. logo

NRx Pharmaceuticals, Inc.

NRXP

1.63 USD

Daré Bioscience, Inc. logo

Daré Bioscience, Inc.

DARE

3.42 USD

Passage Bio, Inc. logo

Passage Bio, Inc.

PASG

0.704 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)